A rapid RP-HPLC method for the simultaneous estimation of Ivacaftor and Tezacaftor and in silico study of their metabolitic products

Abstract Background This study was designed to develop a reliable method for estimation of Ivacaftor and Tezacaftor in pure its pharmaceutical dosage form by RP-HPLC human plasma. Molecular docking studies were carried out the results visualized using PyMol Discovery studio visualizer (Discovery ver. 2.5). The pharmacokinetic properties such as Swiss ADME pKCSM metabolites M1, M6 M2 predicted. In admetSAR, web-based query tools incorporating molecular built-in interface enable database be queried SMILES. Results A simple, linear, precise, accurate developed validated determination (IVA) (TEZ) Chromatographic separation achieved isocratically on Inspire C18, (4.6 × 250 mm, 5 μm) column at 30 ° C. Mobile phase consisting methanol 0.05% formic acid ratio 95:5 with flow rate 1 mL/min injection volume 20 μl detector used is PDA 235 nm. according ICH guidelines found linearity range TEZ (10–50 μg/mL) IVA (15–75 μg/mL). drugs retrieved from PubChem 2D chemical structures generated SMILES notation Chemsketch Software. structure viewed Swiss-PDB Viewer better understanding molecule toxicity biological activity prediction. Conclusion obtained proposed validation parameters assay confirmed that their combined plasma sensitive selective method. silico has revealed are Lipinski rule. oral bioactivity more when compared (Molinspiration) even though they have weight > 500, but all other Molinspiration M2. Validation isocratic procedure that, regardless how sample purified, characterized good linearity, sensitivity, reproducibility, specificity, low values LOD (0.090 LOQ (0.275 From results, it quite evident great potential against cystic fibrosis.